InVivo Therapeutics to Present at 34th Annual Symposium of the National Neurotrauma Society
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Richard Layer, Ph.D., InVivo’s Senior Director of
Research, will be giving a poster presentation at the National Neurotrauma Society (NNS) 2016 Symposium to be held June 26-29 in
Lexington, KY. The abstract, titled “Biodegradable Neuro-Spinal Scaffold Promotes Neuropermissive Tissue Remodeling Following
Spinal Contusion Injury in Rats” will be published electronically in the Journal of Neurotrauma immediately prior to the
conference.
“It’s important to continue to raise awareness about our novel approach to treating spinal cord injuries. We look forward to our
participation in the NNS symposium and to continued outreach to the research community,” Mark Perrin, InVivo’s Chief Executive
Officer and Chairman, said.
A copy of the abstract will be available after the conference on InVivo’s website: https://www.invivotherapeutics.com/research-clinical-development/abstracts-and-publications
About The INSPIRE Study
The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and
Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury, is designed to demonstrate the safety and
probable benefit of the Neuro-Spinal Scaffold™ for the treatment of complete T2-T12/L1 spinal cord injury in support of
a Humanitarian Device Exemption (HDE) application for approval. For more information, refer to https://clinicaltrials.gov/ct2/show/study/NCT02138110.
About the Neuro-Spinal Scaffold™ Implant
Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the
decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity
formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal
Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated
in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord
injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on
treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D.,
Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who
now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American
Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational
Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered
in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
Investor Relations
bluque@invivotherapeutics.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160623005160/en/